Screener
Mannkind MNKD Q2 2026 earnings
Reported August 5, 2026 · After market close
Revenue$109.4MBeat by $1.3M
EPS-$0.06Miss by $0.05
Revenue estimate$108.1M
EPS estimate-$0.01
“This was a transformative period for MannKind, during which we delivered all three major catalysts we set out to achieve in 2026. The two recent FDA approvals are expected to fuel our near-term growth opportunities to help patients living with diabetes, heart failure and CKD. The positive Phase 1b INFLO-1 results for MNKD-201 reduces development risk and strengthens our confidence in the ability of our platform to help people living with IPF and other fibrotic diseases. Together, these milestones validate our diversification strategy and position MannKind for sustainable growth.”
Next report
Nov 4, 2026 (in 2 months)Revenue estimate$110.3M
EPS estimate-$0.08
Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Mannkind report Q2 2026 earnings?
- Mannkind (MNKD) reported Q2 2026 earnings on August 5, 2026 after market close.
- What were Mannkind's Q2 2026 revenue and EPS?
- Mannkind reported revenue of $109.4M and eps of $-0.06 for Q2 2026.
- Did Mannkind beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $108.1M by $1.3M. EPS missed the consensus estimate of $-0.01 by $0.05.
- How did Mannkind's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 42.9% from $76.5M a year earlier.
- Where can I find Mannkind's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-335016) and the 10-Q periodic report (0001193125-26-335054) directly on SEC EDGAR. The filing index links above go to sec.gov.
